Healthcare Stocks

Another feather in Prescient Therapeutics’ (ASX:PTX) cap, bags new US Patent for PTX-100

 Another feather in Prescient Therapeutics’ (ASX:PTX) cap, bags new US Patent for PTX-100

Summary Prescient Therapeutics received new US Patent from the USPTO for companion diagnostic for PTX-100. It is another significant move for PTX in building a deep product pipeline of personalised targeted therapies and tools for treating canc...

Read More...
Impressive! Prescient Obtains Key Licenses for Next Generation Immunotherapy Platform

Impressive! Prescient Obtains Key Licenses for Next Generation Immunotherapy Platform

Summary Prescient obtains two key licenses from world immunotherapy leader, University of Pennsylvania and Oxford University to create a revolutionary cancer therapy platform called “OmniCAR”. OmniCAR platform would allow extraordin...

Read More...
Prescient Now the Outright Owner of IP Resulting from CAR-T Collaboration

Prescient Now the Outright Owner of IP Resulting from CAR-T Collaboration

ASX-listed Australia based clinical-stage oncology player Prescient Therapeutics Limited (ASX:PTX) is engaged in the development of new drugs that demonstrate significant promise as potential innovative therapies for the treatment of challenging canc...

Read More...
Prescient’s Clinical Trials for PTX100 Progressing Well; Moves to Next Stage

Prescient’s Clinical Trials for PTX100 Progressing Well; Moves to Next Stage

Clinical trials are being shuttered in increasing numbers in Australia because of the challenges posed by COVID-19; however, one clinical-stage oncology company Prescient Therapeutics Limited (ASX:PTX) continues to march ahead. The Company has a str...

Read More...
Prescient Reports March 2020 Quarterly Update; Cash Reserves at $8.2 Million

Prescient Reports March 2020 Quarterly Update; Cash Reserves at $8.2 Million

Australian based clinical-stage Oncology company Prescient Therapeutics Limited (ASX:PTX), recently reported operating highlights and financial outcomes for the March quarter 2020. The Company is engaged in the development of new drugs that demonstr...

Read More...
Prescient Therapeutics’ Operations Remain Unscathed by COVID-19 Pandemic

Prescient Therapeutics’ Operations Remain Unscathed by COVID-19 Pandemic

The Coronavirus has become a health threat across the globe and as per World Health Organization (WHO) until now this pandemic has resulted in over 72,744 deaths and infected more than 1,282,931 worldwide in just a few months (8 April 2020, 1:57 GMT,...

Read More...
Prescient Therapeutics- A Shining Star Amidst Cancer Space

Prescient Therapeutics- A Shining Star Amidst Cancer Space

1 in 6 deaths is due to cancer As per World Health Organization, Cancer is the 2nd major cause of death globally, and is responsible for an ~9.6 million deaths in 2018. Worldwide, about one in six deaths is owing to cancer. Demand for effective can...

Read More...
Prescient Therapeutics Update on Half Year Financials: Positive Clinical Development Continued

Prescient Therapeutics Update on Half Year Financials: Positive Clinical Development Continued

Prescient Therapeutics Limited (ASX: PTX) is an Australian based clinical-stage oncology company which is into small molecule drug development focused on new drugs for the treatment of a range of cancers that have become resistant to front line chemo...

Read More...
Mapping Prescient’s PTX-200 Progress

Mapping Prescient’s PTX-200 Progress

Known for developing breakthrough personalised medicines using an approach to address specific mutations that drive cancer, thereby providing resistance to front line chemotherapy,  Prescient Therapeutics Limited (ASX: PTX) has been gaining...

Read More...
Prescient Therapeutics December 2019 Quarterly Update Unveiling Strong Clinical Progress

Prescient Therapeutics December 2019 Quarterly Update Unveiling Strong Clinical Progress

Prescient Therapeutics Limited (ASX: PTX), an Australian based clinical-stage Oncology company, dedicated towards the treatment of an array of challenging cancers with significant unmet need has recently reported operating highlights and financi...

Read More...
Prescient’s “BASKET” Approach Transforming Future Clinical Trials

Prescient’s “BASKET” Approach Transforming Future Clinical Trials

Clinical-stage oncology company, headquartered in Melbourne, Australia, Prescient Therapeutics (ASX:PTX) (“Prescient”), develops personalised medicines to defeat cancer taking an approach to address mutations that cause cancer. Current &...

Read More...
Ad

GET A FREE STOCK REPORT

Top Penny Picks under 20 Cents to Fit Your Pocket! Get Exclusive Report on Penny Stocks For FREE Now.

We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it. OK